Adagrasib pembrolizumab combo shows promise for KRASG12C-positive NSCLC

Share :
Published: 21 Oct 2023
Views: 94
Dr Pasi Janne - Dana-Farber Cancer Institute, Boston, USA

Dr Janne speaks to ecancer about the phase II KRYSTAL-7 trial which reviewed the efficacy and safety of adagrasib with pembrolizumab in patients with treatment-naïve, advanced non-small cell lung cancer harbouring a KRASG12C mutation.

The trial was presented during the ESMO Congress 2023, held in Madrid, Spain.

The study found adding adagrasib to pembrolizumab in patients with advanced, unresectable, or metastatic NSCLC with KRASG12C mutation showed “encouraging preliminary activity” especially in patients with high PD-L1 expression, and the team are looking towards a phase III study next.